Nevin D N, Brunzell J D, Deeb S S
Department of Medicine, University of Washington, Seattle 98195.
Arterioscler Thromb. 1994 Jun;14(6):869-73. doi: 10.1161/01.atv.14.6.869.
Familial combined hyperlipidemia (FCHL) is an oligogenic disorder, with family members having elevated apolipoprotein B-100 levels and either elevated plasma cholesterol or triglyceride levels or both. Obligate heterozygous parents of children with lipoprotein lipase (LPL) deficiency express a mild FCHL phenotype. Of patients with FCHL, 36% have diminished postheparin LPL activity and mass values that are comparable with those of obligate heterozygotes for LPL deficiency. It is hypothesized that heterozygosity for mutations in the LPL gene could contribute to FCHL in this subset of patients. Single-strand conformation polymorphism (SSCP) analysis, direct DNA sequencing, and Southern blot analysis were used to examine exons 1 through 9 and exon-intron junctions of the LPL gene in 20 patients with FCHL and low LPL activity and mass. One subject had a substitution (GAC-->AAC) in exon 2, changing Asp9 to Asn. Two subjects had a previously undescribed "silent" substitution (GTG-->GTA) in exon 3 at Val108. Three patients had a premature termination at codon 447 in exon 9 resulting in truncation of the mature protein by two amino acids. In addition to SSCP analysis, exons 4, 5, and 6, where almost all mutations in LPL-deficient patients have been found, were sequenced and no additional mutations were found. Southern blot analysis of the LPL gene revealed one subject with heterozygous loss of an EcoRI site but without an abnormality in Stu I restriction fragments; this mutation is therefore unlikely to be functionally significant. The substitutions identified at codons 9 and 447 have previously been found not to affect lipolytic activity when expressed in vitro.(ABSTRACT TRUNCATED AT 250 WORDS)
家族性混合性高脂血症(FCHL)是一种寡基因疾病,其家庭成员的载脂蛋白B - 100水平升高,血浆胆固醇或甘油三酯水平升高,或两者均升高。患有脂蛋白脂肪酶(LPL)缺乏症儿童的杂合子父母表现出轻度FCHL表型。在FCHL患者中,36%的患者肝素后LPL活性和质量值降低,与LPL缺乏症的杂合子相当。据推测,LPL基因突变的杂合性可能导致这部分患者发生FCHL。采用单链构象多态性(SSCP)分析、直接DNA测序和Southern印迹分析,检测了20例FCHL且LPL活性和质量较低患者的LPL基因外显子1至9及外显子 - 内含子连接区。一名受试者外显子2有一个替换(GAC→AAC),将Asp9变为Asn。两名受试者外显子3在Val108处有一个先前未描述的“沉默”替换(GTG→GTA)。三名患者外显子9的447密码子处出现提前终止,导致成熟蛋白截短两个氨基酸。除了SSCP分析外,还对几乎所有LPL缺乏症患者发现突变的外显子4、5和6进行了测序,未发现其他突变。LPL基因的Southern印迹分析显示一名受试者EcoRI位点杂合性缺失,但Stu I限制性片段无异常;因此,该突变不太可能具有功能意义。先前发现在体外表达时,9和447密码子处的替换不影响脂解活性。(摘要截短至250字)